South Africa’s largest drugmaker, Aspen Pharmacare, is banking on new production lines in insulin and GLP-1 medicines to drive a financial turnaround after recent earnings pressure. The company disclosed that revenues from its insulin contract with Novo Nordisk could begin contributing around R300 million in fiscal 2026, with projections topping R1 billion by 2027, Reuters reported.
Management explained that the commercial rollout follows the completion of technical validation at its sterile manufacturing facilities, initially developed for COVID-19 vaccines but now being redirected to chronic disease therapies, as outlined in Engineering News.
At the same time, Aspen is advancing into the global market for GLP-1 drugs, widely used for diabetes and weight management. The firm has secured licensing for generic versions of semaglutide and is pursuing registrations that could enable supply to emerging markets and Canada from late 2026, as highlighted by MarketScreener.
Industry analysts note that the pivot allows Aspen to diversify away from its traditional portfolio while taking advantage of growing global demand for diabetes and obesity treatments. They add that, if successful, the initiatives could significantly lift Aspen’s profit margins and restore investor confidence, as reflected in coverage by Reuters.
